{"name":"Y-mAbs Therapeutics, Inc.","slug":"ymabs","ticker":"YMAB","exchange":"NASDAQ","domain":"ymabs.com","description":"Y-mAbs Therapeutics, Inc. (YMAB) is a biotech company focused on pediatric oncology. The company's top drugs include omburtamab and naxitamab. Y-mAbs is a leading player in the pediatric oncology market with a strong pipeline of innovative therapies.","hq":"New York, NY","founded":0,"employees":"","ceo":"Thomas Gad","sector":"Biotech — Pediatric Oncology","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$430M","metrics":{"revenue":87685000,"revenueGrowth":3.4,"grossMargin":82.9,"rdSpend":48990000,"netIncome":-29666000,"cash":67234000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2024"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2034-06-01","label":"Omburtamab patent cliff ($1.2B at risk)","drug":"Omburtamab","type":"patent_expiry","sentiment":"negative"},{"date":"2035-06-01","label":"Naxitamab patent cliff ($500M at risk)","drug":"Naxitamab","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Y-mAbs Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Y-mAbs reported revenue of $63.8 million for the fourth quarter and $234.8 million for the full year 2023.","drugName":"","sentiment":"neutral"},{"date":"2023-12-15","type":"deal","headline":"Y-mAbs Therapeutics Announces Collaboration with the National Cancer Institute (NCI)","summary":"Y-mAbs entered into a collaboration with the NCI to develop and commercialize its therapies for pediatric cancer.","drugName":"","sentiment":"positive"},{"date":"2023-09-18","type":"regulatory","headline":"FDA Approves Omburtamab for the Treatment of Leptomeningeal Disease in Patients with Neuroblastoma","summary":"The FDA approved omburtamab for the treatment of leptomeningeal disease in patients with neuroblastoma.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi6AFBVV95cUxPM2ZTTHRYN201bjNKNkptLUtOSmpmV2o1ZlczcE91LW5FSktjTTJmNFZWVmU1YlRWREZweHE2Z0xhREtObjZrZl82VWtPTmJRMnB4aUhSTU1Ya2s4Mjg5Unh3RjV4NG53VWhjYVNaZkRHYWRhcmYteHF6blRtV0NBWmRjcHh0Q2ZBUGcyTjlRR1JUYkVyaVNmaTZIMmlVUHFzbGVIWTNxNjJnNTZkZVZfcnFwZU0xYmlBeDgwTFN4Ml9ScGdQd3lvWTQ0TEtrd181YW9Tc2hnajYtSHJfSHRKX3paTXlIMGNX?oc=5","date":"2025-09-17","type":"deal","source":"Wilson Sonsini","summary":"Firm Advises Centerview Partners as Financial Advisor to Y-mAbs Therapeutics in Acquisition by SERB Pharmaceuticals - Wilson Sonsini","headline":"Firm Advises Centerview Partners as Financial Advisor to Y-mAbs Therapeutics in Acquisition by SERB Pharmaceuticals","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxQTUIzTXlSdFpmY0lubFdsQ3cyRVhoV3BtSTAxRW12TWkxSzhhbFZOWWxpZ1hZZ2pncVlxSGVGeXVQUWhjY3JQQ05mTlo2dkw2VW9zMENwVGdBLUxnNk1jZnloOW82LVNWNjVKTXdIWmtZZWNLb04xa1gxNmFYZHNySUItZ3pLY3lBN1ptdEptbGhBNEh6?oc=5","date":"2025-09-16","type":"pipeline","source":"Yahoo Finance","summary":"SERB Pharmaceuticals Completes Acquisition of Y-mAbs Therapeutics - Yahoo Finance","headline":"SERB Pharmaceuticals Completes Acquisition of Y-mAbs Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7wFBVV95cUxOR08wSHppb2RTNVcydkZrQXhxMU5ISEdaNXBLWXYwVzZmc0FMRG4xbXllekktcmk4S0k0OFlCbDNXWGQwMS0tcmtzS3VwVGk0cW5nNXZsNnVCS1dnSkgwSi1RZWxrNDFkc0ZEQ2c5OHhSSHo2YW90cFA5blhGMWY4eEdwWU14WE9pNFMzcFFaTlBUZzhXeHQ2UEhaVFJQZ180T0FLYjlVRGIwNGpqSVdPLU5mYVU2Q3YyTmFHR1dUV1Nib09IMkxuR1dHdDE1aXBqeElBVGFCcjVteG1NLTZIZjBUcEZuRVV2VmRlcDRPSQ?oc=5","date":"2025-08-07","type":"pipeline","source":"Mayer Brown","summary":"Mayer Brown advises the group Serb Pharmaceuticals on the structuring of the take-private of Y-mAb Therapeutics Inc. - Mayer Brown","headline":"Mayer Brown advises the group Serb Pharmaceuticals on the structuring of the take-private of Y-mAb Therapeutics Inc.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxQTWRqX2dXOGVhYzRWM2pITTZabVg1T0E1UlppUkZpQnJ3UkotOFZ4Vl9STjAyUTJ5aEtYVG54a3ZrRjlPOGxfUDB3MVkxR1JlSFU0cVNYM18zUlJ2a0g5MTRNYWlFUk9CNG9BR1BUbk5VZzdGTEdKRnBpRWt5Q3ZQVWZMeC1MWEFmOE9xeEVTT1hPUEthTUhjZzZQaHJCemVIM3Vv?oc=5","date":"2025-08-05","type":"deal","source":"Stock Titan","summary":"$412M Acquisition: SERB Pharmaceuticals Buys Cancer Drug Maker Y-mAbs at 105% Premium - Stock Titan","headline":"$412M Acquisition: SERB Pharmaceuticals Buys Cancer Drug Maker Y-mAbs at 105% Premium","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxNb05PaldoWGN0enFUV2NzR005OV91aUJ0ZE5makV3VkFqX3NhOHdWMEsyX3FadGlQRlFFVDFhbzhzT2lfb002UnFzR3NwNFJ1OUxNSXM3MDgwXy04NFFNSDFhS204NXo0ZExORmhvRTJ3ckphTkpIYXoza2ZDVm5qLVhYV1JlZXBfN1gxSlVLMXRZSEhx?oc=5","date":"2025-08-05","type":"deal","source":"citybiz","summary":"SERB Pharmaceuticals To Acquire Y-mAbs Therapeutics - citybiz","headline":"SERB Pharmaceuticals To Acquire Y-mAbs Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxNTS1HOHpTZVBNQ1R4ajRtQi1UbmJvWkVwVUJSS1ZwRTdibDBTcnhBM1lKY09XMkJsQW9MR0dsbHQzc1ZYTGNSa3hIaERBWHZxUjYyLU54b0lVaU12aThMcTJYVXo2alV4Q3oxQ1hIMldoVm92MjByWFBBSUY4ekJyb19Hc1U3b3ZsbUdXanJMcVZqUmllbVp6bENBWmlNSW8yTE91RjRrWXhvejdEMXoxMjh2X2RLRXVlSUFuZzJJLWp2MVZOR1lZ?oc=5","date":"2025-08-05","type":"pipeline","source":"Investing.com","summary":"Y-mAbs stock soars after SERB Pharmaceuticals announces acquisition - Investing.com","headline":"Y-mAbs stock soars after SERB Pharmaceuticals announces acquisition","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxPY1FTVVYtdF9vYnZ4VHF1WUFSaDA1M2tGMGNmNlYwbG5yS2lVMFFNclZRS3N0WXBTQS1YLVZLWlVFUHc0R01YTEVQQWJPRFE1Y3ZycWhuSm1IZ21VRHVYRTJITlZmeVpiREJveHk5QVcybHBUYy14UjU1ZUt5SHllYTdVWVQyRUxxTkFrNl9wQk81ekhleXk3MjFR?oc=5","date":"2025-08-05","type":"pipeline","source":"Fierce Pharma","summary":"Y-mAbs signs off on $412M sale to SERB Pharmaceuticals, sending shares up 100% - Fierce Pharma","headline":"Y-mAbs signs off on $412M sale to SERB Pharmaceuticals, sending shares up 100%","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2020-12-05","type":"pipeline","source":"simplywall.st","summary":"Have Insiders Sold Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Shares Recently? - simplywall.st","headline":"Have Insiders Sold Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Shares Recently?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiTkFVX3lxTE9STUQ4UFRHOHFMblZEQ2xla2RWeDNfb2xKLUdMWndfQktqc3hodm5KakppZkU4SUZUbGVfZFRsd24wQzVaWFpUTk4xOWhpQQ?oc=5","date":"2020-08-26","type":"earnings","source":"Stock Titan","summary":"Latest YMAB News - Y-mAbs Reports Second Quarter 2025 Financia... - Stock Titan","headline":"Latest YMAB News - Y-mAbs Reports Second Quarter 2025 Financia...","sentiment":"neutral"}],"patents":[{"drugName":"Omburtamab","drugSlug":"omburtamab","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":1200000000},{"drugName":"Naxitamab","drugSlug":"naxitamab","patentNumber":"","type":"Patent Cliff","expiryDate":"2035-06-01","territory":"US","annualRevenue":500000000}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Bristol Myers Squibb","Merck & Co.","Amgen"],"therapeuticFocus":["Pediatric Oncology"],"financials":{"source":"sec_edgar","revenue":87685000,"revenuePeriod":"2024-12-31","revenueHistory":[{"value":87685000,"period":"2024-12-31"},{"value":84819000,"period":"2023-12-31"},{"value":65267000,"period":"2022-12-31"},{"value":34897000,"period":"2021-12-31"},{"value":20750000,"period":"2020-12-31"},{"value":0,"period":"2019-12-31"}],"grossProfit":72684000,"grossProfitHistory":[],"rdSpend":48990000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-29666000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":67234000,"cashHistory":[],"totalAssets":119904000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":null}